Filing an Abbreviated New Drug Application with the FDA costs approximately $365,000 plus additional administrative fees

Overview Debates Related claims Topics

Mark Cuban Cost Plus Drug Company developed modular drug manufacturing units housed within tractor-trailer-sized pods

Florida pain management clinics historically operated affiliated on-site pharmacies that exclusively dispensed OxyContin without real-time prescription tracking databases

Cost Plus Marketplace sells sterile injectables to clinics and hospitals at a transparent markup of 10% or 12% above cost

Anthropic acquired Mithril Medicine, a one-person biotechnology company developing therapies for two rare forms of muscular dystrophy

Merck voluntarily withdrew the anti-inflammatory medication Vioxx from the market after clinical data linked Vioxx to tens of thousands of fatal strokes

Mark Cuban proposes requiring nonprofit hospitals to publish their entire detailed general ledgers and all procurement receipts publicly

The United States Congress passed the Controlled Substances Act in 1970 during the presidential administration of Richard Nixon

Mithril Medicine advanced an antibody treatment candidate for muscular dystrophy from initial concept to proof of principle in mice within 18 months

United States government involvement in Flávio Bolsonaro's arrival in the United States in October 2026 was limited to granting visas

Anthropic published an outline detailing its strategy to integrate artificial intelligence across every stage of the drug discovery process

Nonprofit hospitals in the United States are legally required to maintain formal financial assistance programs for patients

Mark Cuban Cost Plus Drug Company pays affiliated retail pharmacies a $12 fill fee per prescription under the Team Cuban Card program

Mark Cuban proposes mandating complete public disclosure of all contracts and general ledgers for healthcare entities receiving taxpayer funds

Mark Cuban Cost Plus Drug Company can change its Dallas manufacturing production line every four hours to produce different medications

The United States federal government became the first customer to purchase a modular drug manufacturing pod from Mark Cuban Cost Plus Drug Company

Mark Cuban's direct hospital contracting model removes requirements for prior authorizations and claims denials by trusting physician determinations

Anthropic set a target to advance a drug candidate developed with Mithril Medicine into clinical trials by the end of 2028

Eight United States states allow payments made outside an insurer network at lower prices to count toward patient deductibles

Each modular drug manufacturing pod developed by Mark Cuban Cost Plus Drug Company costs approximately $20 million

Administrative services only providers and pharmacy benefit managers frequently generate hidden profit margins through medical and pharmaceutical spread pricing